Enhertu
-
April 6, 2022
Essential Breast Cancer Treatment Trends in 2022: Webinar Highlights
Sarah StanleyWomen with breast cancer often face an overwhelming amount of information to sort through and decisions to make. Whether newly diagnosed or starting a next step in treatment, they may wonder: What does the latest research say about my type of breast cancer? Should I enroll in a clinical trial? How do I know if I’m receiving my best-possible treatment? Every day, Cancer Commons… Read more »
-
April 8, 2020
Tucatinib and Trastuzumab Deruxtecan Show Promise in HER2+ Breast Cancer
Smruti Vidwans, PhDIn 1998, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab (brand name Herceptin) for people with HER2-positive metastatic breast cancer. Overnight, HER2+ metastatic breast cancer became treatable (though not curable). Subsequent successful clinical studies led to use of trastuzumab earlier in the breast cancer journey—after surgery—to help prevent recurrence, as well as in earlier-stage HER2+ breast cancer. Meanwhile, the FDA approved… Read more »